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In this chapter, we review salient characteristics, recent research, and particular areas of contro-
versy surrounding progestin-only contraceptive injectables and implants. Progestin-only contraceptive
injectables and implants are ideally offered as part of a wide range of contraceptive options. The ad-
vantages of these progestin-only contraceptive methods include convenience, high efﬁcacy, and ability
to be used by women who cannot use contraception containing oestrogen. We do not provide an
exhaustive review of these methods, but highlight areas of interest.
Composition and mechanism of action
Three progestin-only injectables are available: (1) depot medroxyprogesterone acetate (DMPA),
150 mg/ml, provided intramuscularly (DMPA-IM, marketed as Depo-Provera®); (2) depo-subQ provera
104™,104mg/0.65ml, a subcutaneous formulationofDMPA (DMPA-SC)with30% lowerdosage ofDMPA;
and (3) norethisterone enanthate (NET-EN) 200mg/ml, provided intramuscularly. DMPA-SC packaged in
Uniject™ (apreﬁlled, sterile, non-reusable subcutaneous injection system) is referred to as SayanaPress®;
DMPA-SC in a single-dose, preﬁlled glass syringe as Sayana® [1]. These three injectable methods prevent
pregnancy primarily through ovulation suppression; possible secondarymechanisms include thickening
of cervical mucus or endometrial thinning [2]. Combined injectable contraceptives, containing an oes-
trogen and progestin, are uncommonly used in family planning programmes and not discussed here.
Hormonal implants consist of one or two small (40e44 mm long), thin (2.0e2.5 mm diameter),
ﬂexible, non-biodegradable rods [3,4]. Three implants are currently available. The one-rod implant,
Implanon® (and its successor Implanon NXT®) contains 68 mg of etonogestrel (ENG) [4]. Implanon
NXT® is radiopaque and supplied in a preloaded, single-use, disposable applicator that facilitates
correct subdermal insertion; it is otherwise identical to Implanon® [5]. Both two-rodmethods, Jadelle®
and Sino-implant (II)®, contain 150 mg of levonorgestrel (LNG), 75 mg in each rod [3,6], and are
supplied with a single-use disposable trocar [7]. Production of the ﬁrst-generation implant Norplant®,
which contained 216 mg of LNG in six rods, was discontinued in 2008 [8]. Implants continuously
release low amounts of progestin, which inhibits ovulation and thickens cervical mucus [3,4].
Contraceptive effectiveness: typical and perfect use
‘Typical use’ pregnancy rates reﬂect effectiveness under actual usage patterns, which include
inconsistent or incorrect use; ‘perfect use’ pregnancy rates refer to effectiveness when used precisely
according to direction. Data from the USA suggest that 6% of women with typical use and 0.2% with
perfect use of DMPA would experience an unintended pregnancy within the ﬁrst year of use [2,9].
Typical use pregnancy rates may vary by context and population [10]. Several studies report equivalent
contraceptive efﬁcacy between DMPA-IM and DMPA-SC [11], and similar pregnancy rates (0.4 per 100
women) for DMPA given at 90-day intervals and NET-EN given at 60-day intervals [12].
Implants are effective within 24 h of insertion [3,4]. They have the highest effectiveness of any
contraceptive method, with 0.05% of typical and perfect users expected to experience an unintended
pregnancy in the ﬁrst year of use [9]. Implanon® and Implanon NXT® are labelled effective for 3 years of
use [13,14]. Sino-implant (II)® and Jadelle® are labelled effective for 4 and 5 years of use, respectively
[3,6,14]. The cumulative pregnancy rate during clinical trials of Jadelle®was 0.3% at 3 years and 1.1% at 5
years [3], comparable to the 5-year pregnancy rate of female sterilisation (1.3%) [15]. Sino-implant (II)
ﬁrst-year pregnancy probabilities are 0.0e0.1%, and cumulative 4-year pregnancy probabilities are
0.9e1.06% [6]. In 11 worldwide studies of Implanon®, no pregnancies occurred with the implant in situ
[4]. In the ﬁrst year of typical use, implants are about 120 times more effective than injectables and 180
times more effective than combined contraceptive pills [9].
Effectiveness in overweight or obese women
Progestin-only injectables are not expected to have lower efﬁcacy in overweight or obese women
[2,16]; however, data are limited [4,17,18]. In later years of use, implants may have lower efﬁcacy in
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and decrease with time after insertion [3]. Results of studies are, however, ambiguous, and the quality
of evidence is low. Although studies examining Jadelle® and Implanon® observed no trend by body
weight [19,20], the World Health Organization (WHO) has recommended that women who weigh
80 kg or more should consider having the LNG implant replaced after 4 completed years because of
concerns about reduced effectiveness [14,21].Eligibility
For most women and most medical conditions, injectables and implants may be used under any
circumstances (WHO Medical Eligibility Criteria [MEC] Category 1) or be generally used (MEC
Category 2) [14,22]. For most conditions, the MEC categorisation is similar for injectables and
implants; differences are mainly among cardiovascular conditions (Category 2 for implants;
Category 3 for injectables). Women with known or suspected pregnancy, unexplained vaginal
bleeding, history of breast cancer, and presence or history of severe liver disease should generally
not use either method (Category 3). The only absolute contraindication (MEC Category 4) is current
breast cancer.
Injectables and implants are suitable for women of any age (including adolescents), parity, marital
status, or reproductive intention (to delay, space, or limit), or for women who are post-abortal, breast
feeding, or living with HIV.Provision of progestin-only injectables and implants
Injectables and implants may be provided any time during a woman's menstrual cycle if it is
reasonably certain she is not pregnant, which can be determined by a pregnancy test or checklist
[21,23e25]. A requirement that a woman needs to be menstruating to receive an injectable or an
implant is an unjustiﬁed barrier to service provision [26]. These methods may be initiated without a
pelvic examination, blood or other routine laboratory tests, cervical cancer screening, or a breast ex-
amination [14].
DMPA-IM and NET-EN are injected into the upper arm or buttock. DMPA-SC is labelled for the upper
thigh or abdomen, although the upper arm is preferred in many countries [27,28], and an injection in
this location provides sufﬁcient contraceptive protection for 13weeks [29]. DMPA-IM and DMPA-SC are
administered approximately every 3 months (13 weeks), NET-EN every 2 months (60 days). WHO
advises that repeat injections can be given 2 weeks early or up to 2 weeks late for NET-EN and 2 weeks
early or up to 4 weeks late for DMPA [25,30].
Return to fertility after a DMPA-IM injection averages between 9 and 10 months (i.e. 6e7 months
longer than the expected duration of effect; one study reported a range of 4e31 months) [31,32]. This
may be slightly shorter with NET-EN [33]. Time from cessation of injection to return of fertility is not
associated with number of years of DMPA use. One study reported a median of 30 weeks to return to
ovulation after stopping DMPA-SC [34]. Additional contraceptive protection is not required, although
this ‘grace period’ (for late use) for DMPA may vary by country [24].
Implants are inserted superﬁcially beneath the skin of the upper arm [3,7]. Insertion usually takes
1e2mins and removal 3e5mins. A client does not need to commit to implant use for the full length of its
labelled use to receive it [14,35]. Complications of insertion or removal are uncommon (less than 2%)
[3,4]. Difﬁculty of removing the implant is directly correlated with deep insertion [3,14]. Return to
fertility is prompt; in clinical trials of Implanon®, several pregnancies occurred within 7e14 days after
removal [4]. After removal of LNG implants, pregnancy occurs within 6months in 60% of women,1 year
in 80%, and 2 years in 90% [3]. These rates are similar to those among women who do not use contra-
ception [9]. Routine follow-up visits are not needed [14], but healthcare providers should indicate to the
woman that she can return any time, whether for advice, reassurance, treatment of side-effects, or
removal.Womenshould alsobe instructed to return in theeventof adelayedperiodafter severalmonths
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heavy bleeding, or signs of infection at the insertion site. Programmes should provide awrittendate that
the implant needs to be removed or replaced, and have a system of follow up for removals.
Side-effects and other considerations
Thoughtful counselling, including comprehensive information and anticipatory guidance about
side-effects, is critical to ensuring informed contraceptive choice and quality service provision [35,36].
Below, we review selected programmatically important side-effects of progestin-only methods; other
sources provide information on other potential side-effects (e.g. headache, breast pain, abdominal pain,
sexual side-effects, metabolic effects, drug interactions, and mood changes), and potential advantages
(e.g. reductions in grand mal seizures or sickle cell crises, reduced pain from endometriosis, and
decreased risk of pelvic inﬂammatory disease) [2].
Changes in menstrual bleeding patterns
Changes in menstrual bleeding patterns (e.g. lighter or heavier bleeding, prolonged or irregular
bleeding, or amenorrhoea) are a major cause of hormonal contraceptive discontinuation [2]. Progestin-
only methods induce more menstrual irregularity than combined methods [37]. Most women will
experience irregular bleeding patterns in the ﬁrst year of progestin-only contraceptive use, although
irregularity reduces over time. [3,38,39] For DMPA-IM and DMPA-SC users, the proportion of women
experiencing amenorrhoea increases over time (to 40e50% after 1 year and 80% after 5 years of DMPA
use) [2,40e42]; these rates may be lower with NET-EN [12]. Amenorrhoea among LNG implant users is
lower than among injectable users, and remains relatively constant over time (about 11%) [40]. Use of
ENG implants may be associated with fewer bleeding or spotting episodes and signiﬁcantly more
amenorrhoea (22% in one study) than LNG implant users [4,39]. Despite bleeding irregularities, hae-
moglobin levels rise with implant use [3], and DMPA and NET-EN may protect against anaemia [14]. A
number of practical approaches are available to managing bleeding changes [14,43].
Weight gain
Weight gain is another commonly cited reason for discontinuing (or not initiating) hormonal
contraception [44]. In a recent systematic review [45], studies comparing DMPA against combined
hormonal contraceptives reported no differences in weight change between methods, but some
studies comparing DMPAwith a non-hormonal method or no method suggested slightly more weight
gain (less than 2 kg) among DMPA users. A prospective study from South Africa reported that
adolescent injectable users gained more weight over 4e5 years of use (average of 6.2 kg) than users of
the combined oral contraceptive pill, discontinuers, and non-users of contraception (average weight
gain 2.3 kg, 2.8 kg, and 2.8 kg, respectively) [46]. Differences inweight gain between DMPA-IM, DMPA-
SC, and NET-EN have not been reported [12,42,47]. Two studies comparing Norplant® against non-
hormonal intrauterine device users showed increased weight change (0.47e1.10 kg), whereas two
studies comparing Norplant to DMPA or Jadelle® found no differences [45]. In trials of Jadelle®, average
weight gain over 5 years was 9 pounds, with 20% of women gaining at least 10 pounds in the ﬁrst year
and 50% gaining at least 10 pounds after 5 years [3]. It is unclear how much of this weight gain is
attributable to the contraceptive.
Bone mineral density
Both DMPA-IM and DMPA-SC currently carry a US FDA black-box warning [48,49] discouraging use
for more than 2 consecutive years as evidence shows that prolonged use reduces bone mineral density
(BMD); however, BMD loss generally seems to be temporary and reversible [2]. Although some
observational studies suggest DMPA may increase fracture risk [50], currently available randomised
data are insufﬁcient to conﬁrm an increase in any clinically relevant outcome (i.e. bone fracture) [51].
Associations observed in some observational studies [50] could be a result of confounding [52]. WHO
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[53,54], and some scientists have called for removal of the FDA black box warning [55]. Data on ENG-
and LNG-implants and BMD are mixed, but whether any potential change are clinically signiﬁcant is
unknown [2].
Ectopic pregnancy
Because of their effectiveness at preventing pregnancy, injectables and implants reduce the overall
risk of ectopic pregnancy. The ectopic pregnancy rate with Jadelle is less than 0.5 per 1000 woman-
years [3]. This rate is signiﬁcantly below the ectopic pregnancy rate for women who do not use
contraception (2.7 to 3.0 ectopic pregnancies per 1000 woman-years). Clinicians, however, need to
remain alert to the possibility of ectopic pregnancy in women using implants (or injectables) who
become pregnant or have lower abdominal pain.
Cancer
Progestin-only contraceptives may reduce the risk of endometrial cancer by up to 80% [56], and are
not associated with ovarian cancer [57]. Althoughmost studies suggest no link between progestin-only
injectables and breast cancer [2], two recent studies reported transiently increased risks [58,59].
Studies on progestin-only injectables and cervical cancer report mixed ﬁndings [59,60]. Few data exist
for progestin-only implants and cancer risk, but no increased risk of endometrial or cervical cancer has
been observed with ENG implants [61]. Although one small study [62] reported a potential increase in
risk of breast cancer among implant users, additional data are needed [62].
Satisfaction, continuation and discontinuation
Injectable contraceptive users report appreciating the ability to use the method without others
knowing, freedom from required daily action, and lack of interference with sexual intercourse [14].
Acceptability studies have shown Sayana Press® to be more acceptable than DMPA-IM to women and
providers [27,28,63]. Implant users report liking the convenience (no user action required after
insertion), high efﬁcacy, long duration of use, and lack of interference with sexual intercourse
[14,35,64]. Satisﬁed users tend to be women who do not experience side-effects or who value the
method's positive features enough to tolerate them [64]. User satisfaction, quality of services, and
continuation are related [64].
Continuation rates for implants are high, and higher than for injectables, in both high-resource and
low-resource countries. A WHO analysis of 60 Demographic and Health Surveys (DHS) between 1990
and 2009 found a probability of discontinuation of injectables of 41% at 12 months, 65% at 24 months,
and 74% at 36 months; reasons for discontinuationwere mainly related to the method used or to 'side-
effects and other health concerns' [65]. Continuation of implants in trials and published studies from a
number of countries ranges from 78e96% at 1 year to 50e86% at 3 years [3,4,43,66]. Unacceptable
bleeding changes (and their sociocultural implications) are a main factor in discontinuation, as are
side-effects [3,43,66]. Early discontinuation of implant use does not necessarily represent a problem;
rather, what is to be avoided is discontinuation (of any method) into contraceptive non-use because of
service and programme factors (e.g. stockouts of methods, poor counselling or side-effects manage-
ment) by women who want to avoid unintended pregnancy [67,68].
Service delivery considerations
In addition to being provided by doctors, injectables and implants can be provided safely and
effectively by many other cadres of healthcare providers, including clinical ofﬁcers, nurses, midwives,
auxiliary nurses, auxiliary nurse-midwives, and (for injectables) community health workers [69]. Such
‘task shifting’ or ‘task sharing’ (i.e. delegation of appropriate tasks to less-specialised health cadres), is
critical in addressing shortages of medical professionals and expanding access to contraceptive services
for populations in need [69]. Availability of Sayana Press® could help improve clinic injection services
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perhaps facilitate ‘home use’ (administration at home by a family member or woman herself through
self-injection) [1,71].
Implant services can be delivered in static health sites or by mobile outreach (where a mobile team
of service providers regularly visits under-served rural and periurban areas) [3,35,72]. Service sites
must provide privacy, counselling, good surgical technique, and infection prevention. Access to implant
removal as well as insertion must be regularly and reliably available. Implant and injectable (and other
family planning) services can be integrated with postpartum visits, postabortion care, and child
immunisation sessions. Strong links with community health programmes are important. Ethiopia is
training 15,000 rural community health extension workers (the lowest cadre in its health system) to
insert ENG implants, with referrals for removal made to providers in higher cadres of the health system
[73].
Cost considerations for implants
High-commodity cost has historically limited wider availability of implants [6,35,74,75]; however,
the commodity cost of Jadelle® and Implanon®, once as high as around USD $24 per unit [74], has
recently been reduced to USD $8.50 per unit (similar to Sino-implant-II's commodity cost of around $8
per unit) owing to donor volume guarantees. Over 40 million implants are to be made available be-
tween 2013 and 2018 in low-income countries, as prioritised at the 2012 London FP2020 Summit
[76e78]. Once direct and indirect service costs have been factored in, the cost-effectiveness per couple-
year of protection (CYP) is now comparable to, or better than, the cost-effectiveness of injectables (and
pills), in both low-resource and high-resource countries [75,79,80].
Use and popularity of injectables and implants in family planning programmes
Globally, injectables account for 6% of modern method contraceptive prevalence (MCPR) among
women who are married or in union [81]. Injectables account for 43% of MCPR in sub-Saharan Africa,
46% in Southern Africa and 49% in Eastern Africa, and are the most widely used method in those re-
gions. In many low-resource countries, injectables account for one-half ormore of modernmethod use,
including Ethiopia, (76%), Indonesia (66%), Madagascar (65%), Malawi (61%), Burundi (59%), Kenya
(55%), Uganda (54%), Myanmar (50%), and South Africa (47%) [82]. These disparities partly reﬂect the
difﬁculty of accessing even longer-acting or permanent methods in low-resource countries [83]. DMPA
is the most widely available and commonly used injectable formulation [1].
Implants are registered in over 80 countries [8]. Although global use of implants has been below 1%
ofMCPR amongwomenwho aremarried or in union, recent evidence suggests that implant usemay be
rising. About 6 million women were using an ENG implant in 2010 [43]. Marie Stopes International
provided 1.7 million implants in 15 sub-Saharan African countries between 2008 to 2012, with pro-
vision rising from 80,000 in 2008 to 750,000 in 2012 [72]. Ethiopia procured over 2.4 million implants
between 2009 and 2012 compared with 90,000 between 2005 and 2006 [35]. In Zambia, 18 nurse-
midwives at high-volume public-sector facilities inserted more than 22,000 implants in 14 months
[84]. Seven sub-Saharan African countries (Burkina Faso, Ethiopia, Mali, Rwanda, Uganda, Tanzania,
and Zimbabwe) have an implant contraceptive prevalence rate above 2%, with proportionally sizeable
increases between their two most recent Demographic and Health Surveys [35]. The implant contra-
ceptive prevalence rate in Rwanda (6.3% among married women) is the highest in Africa and perhaps
the world. Implants have become the second most popular method in Ethiopia and Burkina Faso, and
the third most popular method in Rwanda.
Use of progestin-only injectables and implants in breastfeeding women 0e6 weeks postpartum
Use of progestin-only methods in breastfeeding women 0e6 weeks postpartum has been
controversial owing to concerns about potential adverse neonatal outcomes [85]. Animal data have
suggested an effect of progesterone on the developing brain; however, limited data on immediate
postpartum DMPA use and neonatal outcomes have not suggested adverse effects, although data on
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period was not associated with adverse maternal clinical effects, signiﬁcant maternal metabolic
alterations, or decreased infant weight [86]. Recommendations among normative bodies differ
considerably. WHO guidance states risks of progestin-only contraceptive use by breastfeeding
women 0e6 weeks postpartum outweigh beneﬁts (MEC Category 3) [22]. The US Centers for Dis-
ease Control and Prevention assigns MEC Category 2 (beneﬁts outweigh risks) to progestin-only
contraceptive use during the ﬁrst 4 weeks postpartum, and advises that progestin-only contra-
ceptives can be used immediately after birth by breastfeeding women [24]. The UK's Royal College
of Obstetricians and Gynecologists advises no restrictions at any time (MEC Category 1) [87]. The
Society of Gynaecologists and Obstetricians of Canada advises that progestin-only methods be
considered options for postpartum women regardless of breastfeeding status, and may be intro-
duced immediately after delivery [88]. Immediate postpartum provision of implants could offer
greatly expanded programme opportunities in low-resource countries [83], as births are increas-
ingly occurring in facilities, and over 90% of postpartum women want to avoid a subsequent
pregnancy for at least 2 years [89]. WHO addressed this question during a March 2014 expert
meeting to assess newly-available, relevant evidence; recommendations stemming from that
meeting are expected to be available later in 2014.
Possible associations with human immunodeﬁciency virus
The relationship between various hormonal contraceptive methods and human immunodeﬁciency
virus (HIV) has recently been controversial in scientiﬁc and lay circles. Several studies have examined
whether an association exists between speciﬁc methods of hormonal contraception and HIV acquisi-
tion in HIV-negativewomen. Similarly, amongwomen living with HIV, studies have examinedwhether
an association exists between speciﬁc methods of hormonal contraception and (1) female-to-male HIV
transmission, (2) HIV disease progression, or (3) drugedrug interactions with certain antiretroviral
medications.
A recent systematic review [90] clariﬁed that the preponderance of higher-quality epidemiological
data suggest no association between oral contraceptive pills and HIV acquisition, but that the body of
higher quality epidemiological data on progestin-only injectable contraceptives is mixed and difﬁcult
to interpret. Some investigators have reported a 1.5e2.2 times increased risk of HIV acquisition with
contraceptive injectables, whereas other investigators have reported no statistically signiﬁcant as-
sociation. No study in that systematic review reported a statistically signiﬁcant association between
NET-EN and HIV acquisition, but only three studies were available. Limited or no data were available
for contraceptive implants (or patches, rings, and hormonal intrauterine devices). An updated sys-
tematic review of this topic including recently published data is currently under consideration for
publication.
A second systematic review [91] assessed whether use of a method of hormonal contraception by a
woman living with HIV increases risk of female-to-male HIV transmission. Only one study in sero-
discordant couples (in which contraceptive use can be measured in the HIV-infected female partner
and HIV seroconversion can be measured in the male sexual partner) was available [92]. That study
suggested a doubling in risk of female-to-male HIV transmissionwith use of injectables. No statistically
signiﬁcant association was reported for oral contraceptive pills and female-to-male HIV transmission,
but statistical power was limited. Seventeen studies reported mixed results for an association of
hormonal contraception with cervicovaginal shedding among women living with HIV, and generally
did not report any associationwith plasma viral load. Thus, the data for the potential for injectables (or
oral contraceptive pills) to increase female-to-male transmission are limited, and no data exist on this
association for other hormonal contraceptive methods.
A third systematic review [93] assessed whether various hormonal contraceptive methods are
associated with accelerated HIV disease progression. Here, the preponderance of evidence suggests
that women living with HIV can use oral or injectable contraception without concerns related to
HIV disease progression. Data were not available on contraceptive implants and HIV disease
progression.
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hormonal contraceptive method for women living with HIV or at high risk of HIV infection, but added a
clariﬁcation that due to the inconclusivenature of the evidence,womenathigh risk ofHIVusingprogestin-
only injectable contraception should be strongly advised also always to use condoms,male or female, and
otherHIVpreventivemeasures [94].DatapublishedbetweenDecember15,2011and January15,2014were
presented at a WHO meeting on Medical Eligibility Criteria for Contraceptive use in March 2014; recom-
mendations related to hormonal contraception and HIV stemming from this meeting are expected to be
issued in July 2014.
Considerations are ongoing about how to obtain more deﬁnitive evidence. Analytic recommenda-
tions for improving the quality of the observational evidence base have been published [95], and dis-
cussions are ongoing about whether a randomised-controlled trial is feasible and could provide more
deﬁnitive data.
In addition, some antiretroviral medications (such as some protease inhibitors, the non-nucleoside
reverse transcriptase inhibitors efavirenz and nevirapine, and cobicistat-boosted elvitegravir) may
reduce the effectiveness of contraceptive implants (and combined oral contraceptive pills); however,
DMPA (as well as the hormonal IUD) is unlikely to lose contraceptive effectiveness when taken with
any antiretroviral medication [96].
No contraceptive method, other than male or female condoms, is known to provide any protection
against sexually transmitted diseases (STIs), including HIV. All people at high risk of HIV should be
provided with access and empowered to use male or female condoms, and they have a right to know
about the current scientiﬁc uncertainty about a potential, but not deﬁnitive, relationship between
progestin-only injectable contraceptives and HIV acquisition. Data on implants are too scarce to draw
any conclusions.
Highly effective contraception prevents unintended pregnancy, which in turn decreases maternal
and infant morbidity andmortality, and recourse to unsafe abortion. Contraceptive use prevents 44% of
maternal deaths [97], in addition to numerous non-fatal outcomes related to childbirth, such as ﬁstula.
Thus, highly effective contraceptive methods, such as injectable contraception, contribute to saving
lives and improving health and well-being. These effects must be balanced, however, against a po-
tential risk of HIV acquisition if such an association is conﬁrmed, and the public health community
must grapple with how to balance the risks and beneﬁts of various contraceptive options. A recent
modelling study considered the net public health outcome of a reduction in use of injectable contra-
ception in various epidemiological contexts and concluded that, ‘unless the true effect size approaches
(a more than doubling in risk), it is unlikely that reductions in injectable hormonal contraception could
result in a public health beneﬁt, with the possible exception of those countries in southern Africa with
the largest HIV epidemics [98].’
Conclusion
Most women may use injectables or implants in most circumstances. Implants have the highest
effectiveness of any contraceptive method, with an unintended pregnancy rate of about one in 2000 in
the ﬁrst year of use. A lower-dose, subcutaneous formulation of the most widely used injectable DMPA
could hold the promise of improving and expanding injectable services. Low use of contraceptive
implants partly reﬂects the difﬁculty of accessing long-acting or permanent methods in low-resource
countries. Commodity cost of implants has been markedly lowered and their use is rising. Changes in
menstrual bleeding patterns with progestin-only contraceptive use are common, and a chief cause of
discontinuation. Normative bodies differ on guidance regarding progestin-only contraceptive use in
breastfeeding women 0e6 weeks postpartum. Immediate postpartum provision of implants could
offer greatly expanded programme opportunities in low-resource countries, as more births are
occurring in facilities and over 90% of postpartumwomenwant to avoid a subsequent pregnancy for at
least 2 years. The possible association of progestin-only contraceptive with HIV is a controversial issue
with important public health and clinical practice implications, especially for sub-Saharan Africa,
which carries a disproportionate burden of both HIV and maternal mortality.
Research agenda
 Obtain clarity on the relationship between various methods of hormonal contraception with
HIV acquisition in women, female-to-male transmission, and drugedrug interactions with
antiretroviral therapy.
Practice points
 Most women, including adolescents and nulliparous women, may use injectables and im-
plants in most circumstances.
 A woman does not need to be menstruating to receive an injectable or an implant, nor are
blood or other laboratory tests prerequisites to use.
 Changes inmenstrual bleeding patterns with injectables and implants are common. They are
a chief cause of discontinuation, and an important topic for counselling and anticipatory
guidance.
 DMPA-SC, a lower-dose, subcutaneous formulation of the most widely used injectable
(DMPA-IM), provides equivalent efficacy and is preferred by women and providers.
 Return to fertility after a DMPA-IM injection averages 9e10 months.
 The late reinjection grace period for DMPA is 4 weeks in most countries.
 A woman does not need to commit to using an implant for its full length of labelled use in
order to receive it.
 The possible association of injectables and implants with HIV has important counselling and
service implications; countries should consider how best to adapt recent WHO guidance to
their local epidemiological context.
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